ArticleInternational journal of clinical and experimental pathology2019
miR-497 inhibits the carcinogenesis of hepatocellular carcinoma by targeting the Rictor/Akt signal pathway.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- Lipid Nanoparticles as a Platform for miRNA and siRNA Delivery in Hepatocellular Carcinoma.Current drug delivery · 2025Review
- The mTORC2 signaling network: targets and cross-talks.The Biochemical journal · 2024Review
- Role of Non-Coding RNAs in Hepatocellular Carcinoma Progression: From Classic to Novel Clinicopathogenetic Implications.Cancers · 2023Review
- MicroRNA miR-497 is closely associated with poor prognosis in patients with cerebral ischemic stroke.Bioengineered · 2021Article
- MicroRNA-497 induced by Clonorchis sinensis enhances the TGF-β/Smad signaling pathway to promote hepatic fibrosis by targeting Smad7.Parasites & vectors · 2021Article
- Regulation and metabolic functions of mTORC1 and mTORC2.Physiological reviews · 2021Review
- Review
- The Maturation of Tumor Suppressor miR-497 in Hepatocellular Carcinoma is Inhibited by Oncogenic circRNA SCARB1.Cancer management and research · 2021Article
- Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma-A Review.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are involved in regulating various physiologic and pathologic processes of different human diseases including hepatocellular carcinoma (HCC). Our research aimed to investigate the role of miR-497 in migration, invasive ability of HepG2-GS cells and the regulating mechanism. In this study, Rictor was identified as a target gene of miR-497 by informatic software, including Microcosm Targets, miRanda, and TargetScan. MiR-497 or Rictor were silenced or overexpressed in HepG2-GS cells through transfection. The functional assay results showed that Rictor knockdown inhibited cancer cell proliferation, migration and invasion. Overexpression of Rictor inversed the effects of miR-497 on cancer cells growth inhibition. miR-497 regulated protein kinase B, PKB (Akt) signaling pathway by targeting Rictor. MiR-497 increased chemo-sensitivity of HepG2-GS through regulation of Rictor. In conclusion, our research demonstrated that miR-497 inhibits the proliferation, invasion, metastasis, and chemotherapy resistance of hepatoma cells by targeting of Rictor/Akt signal pathway, and miR-497. Thus, Rictor has the potential to be a explored as a biomarker or therapeutic target for diagnosis and treatment of HCC.
Indexed as
Identifiers
31934021PMC6949653W3004938764What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.